Crossover Comparison of MultiHance and Dotarem

Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Timeline

Start

2014-02

Primary completion

2015-03

Completion

2015-03

Outcome

Mixed primary results

registry p <0.0001; ∆Percentage MH better minus DM better 47.6 (95% CI 34.5 to 60.7); Wilcoxon signed-rank test. NCT02070380 ↗

registry p = 0.1295; ∆Percentage MH better minus DM better 7.3 (95% CI -2.0 to 16.5); Wilcoxon signed-rank test. NCT02070380 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gadobenate dimeglumine	Diagnostic / imaging agent	0.05 mmol	—
Subject	Gadobenate dimeglumine	Diagnostic / imaging agent	0.1 mmol	—
Subject	Gadoterate meglumine	Diagnostic / imaging agent	0.1 mmol	—

Indications